Patients Eligible to a Curative Treatment for Primary HCC Clinical Trial
— TOMICOfficial title:
Potential Interest of Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) for the Selection of Patients Proposed for Curative Treatment of a Hepatocellular Carcinoma
| Verified date | October 2023 |
| Source | Hospices Civils de Lyon |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Hepatocellular carcinoma (HCC) is the fifth most common cancer in terms of incidence and the second in terms of mortality. At an early stage, which is based on a low number and size of liver nodules and the absence of extra-hepatic locations (Milan criteria), a curative treatment can be performed, i.e. liver transplantation, surgical resection, or thermo-ablation. These treatments can lead to severe complications, so patients benefiting from them must be carefully selected. The correct identification of all HCC lesions at the time of the therapeutic decision is crucial. MRI is the reference examination for diagnosis but its field of exploration is limited to the upper abdominal area and its sensitivity decreases for nodules of less than two centimetres. Such lesions could actually be HCC that will cause early post-operative progression. Positron Emission Tomography (PET; functional imaging) with fluorodeoxyglucose can provide prognostic information but impacts initial staging in less than 5% of cases. However, PET with fluorocholine (FCH), available in France since 2010, could detect intra- and extra-hepatic HCC lesions not identified by conventional imaging, potentially impacting patient management (e.g. 52% of patients in a small case study). FCH-PET/MRI could therefore be the ideal examination for the initial staging of HCC, combining in a single multimodality investigation the reference morphological imaging technique and an efficient functional one. The hypothesis of this study is that FCH-PET/MRI is able to detect, in patients eligible for curative treatment, additional preoperative intra- and extra-hepatic early or metastatic HCC unseen or equivocal with conventional imaging (CT and MRI) and responsible for recurrence or disease progression at 6 months.
| Status | Completed |
| Enrollment | 61 |
| Est. completion date | January 2, 2023 |
| Est. primary completion date | January 2, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Age =18 years old - Primary HCC proven by histological or imaging examinations (LIRAD 4 or 5) - Eligible for curative treatment (Barcelona criteria) i.e. hepatic transplantation according to Milan criteria, surgical resection, or thermo-ablation, according to a multidisciplinary decision care committee - Affiliated to, or a beneficiary of, a social security system - Written informed consent. Exclusion Criteria: - Patient refusing curative treatment - Patient with HCC not eligible for curative treatment according to conventional imaging (CT, MRI) - Patient with performance status >1 - Contraindication to MRI - Pregnant or lactating woman - Adult ward of court (under guardianship or trusteeship) |
| Country | Name | City | State |
|---|---|---|---|
| France | CHU de Grenoble, Servide d'Hépato-gastro-entérologie | La Tronche | |
| France | HCL, Hôpital de la Croix-Rousse, service d'Hépato-gastro-entérologie | Lyon | |
| France | HCL, Hôpital Edouard Herriot, service d'hépato-gastro-entérologie | Lyon | |
| France | Hospices Civils de Lyon, Hôpital Edouard Herriot, service d'hépato-gastro-entérologie | Lyon |
| Lead Sponsor | Collaborator |
|---|---|
| Hospices Civils de Lyon |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Specificity of FCH-PET/MRI for the detection of preoperative lesions | Specificity of FCH-PET/MRI for the detection of preoperative lesions not visible with conventional imaging techniques and confirmed as being HCC Specificity of preoperative FCH-PET/MRI will be calculated as a ratio of the number of patients with negative FCH-PET/MRI and no additional lesions in histopathology and/or no progressive lesions confirmed at follow-up, to the total number of patients with no additional lesions in histopathology and/or no progressive lesions confirmed at follow-up. | 6 months post-treatment | |
| Secondary | Progression-free survival rates of patients with and without additional lesions visible on FCH-PET/MRI | 24 months post-treatment | ||
| Secondary | Sensitivity of preoperative FCH-PET/MRI for detecting HCC lesions | Sensitivity of preoperative FCH-PET/MRI will be determined as a ratio of the number of patients with positive imaging and additional lesions in histopathology and/or progressive lesions confirmed at follow-up, to the total number of patients with additional lesions in histopathology and/or progressive lesions confirmed at follow-up. | 6 months post-treatment | |
| Secondary | Positive and negative predictive value of FCH-PET/MRI | Positive predictive value will be calculated from the number of patients with positive imaging and additional lesions in histopathology and/or progressive lesions confirmed at follow-up, and the total number of patients with positive imaging. Negative predictive value will be calculated from the number of patients with negative imaging and no additional lesions in histopathology and/or progressive lesions confirmed at follow-up, and the total number of patients with negative imaging. | 6 months post-treatment | |
| Secondary | Specificity and sensitivity of FCH-PET/MRI compared with preoperative MRI findings for extra-hepatic HCC lesions and for intra-hepatic HCC lesions | FCH-PET/MRI examination, up to 2 months before treatment | ||
| Secondary | FCH-PET/MRI findings (positive or negative, and standardized uptake value ratio between lesions and liver or tissue) compared to HCC differentiation by histopathology | FCH-PET/MRI examination, up to 2 months before treatment | ||
| Secondary | Costs of performing FCH-PET/MRI | Direct observation of the realization of FCH-PET/MRI, to be able to reconstitute, in the most reliable way, the cost of the examination (micro-costing method). | FCH-PET/MRI examination, up to 2 months before treatment | |
| Secondary | Incremental cost-effectiveness ratio | Modeling of the patient pathway in terms of resource consumption and efficacy, including the completion of FCH-PET/MRI compared to the usual strategy of patient care | 24 months post-treatment | |
| Secondary | Costs avoided and induced by performing FCH-PET/MRI | 24 months post-treatment |